Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.51 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437332 | 0.93 | UTS2R (0.55) | UTS2RSMYD2CCR3KDM4EALDH1A1 | |
| SCHEMBL12513958 | 0.91 | SLC6A2 (0.54) | UTS2RSMYD2DRD2DRD4DRD3 | |
| SCHEMBL13925242 | 0.87 | SLC5A7 (0.59) | DRD2DRD4DRD3CCR3ALDH1A1 | |
| SCHEMBL12437729 | 0.87 | TP53 (0.49) | UTS2RDRD2DRD4DRD3CCR3 | |
| SCHEMBL12437337 | 0.87 | ALDH1A1 (0.58) | UTS2RSMYD2KDM4EALDH1A1SLC5A7 | |
| SCHEMBL12437330 | 0.86 | SMYD2 (0.51) | UTS2RSMYD2CCR3KDM4EALDH1A1 | |
| SCHEMBL14147057 | 0.85 | GAA (0.58) | UTS2RCCR3ALDH1A1SLC5A7CACNA1G | |
| SCHEMBL12437957 | 0.83 | SLC5A7 (0.51) | SMYD2DRD2DRD4DRD3KDM4E | |
| SCHEMBL12437835 | 0.83 | MCHR1 (0.54) | UTS2RSMYD2CCR3KDM4EALDH1A1 | |
| SCHEMBL12437825 | 0.83 | CCR2 (0.47) | UTS2RSMYD2DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | UTS2R 854/4885SMYD2 2555/4885DRD2 1842/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | UTS2R 854/4885SMYD2 2555/4885DRD2 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.